Poor-prognosis tumours showed upregulation of the stem cell markers LGR5, IGF2BP1, IGF2BP3, and PROM1 (fold change >2), as well as the drug targets CDK1, CDK6, EZH2, KIF11, PLK1, RRM2, TTK, and TYMS (fold change >1) relative to good-prognosis MPNSTs (Supplementary Fig. S15). This evidence concerns the gene EZH2 and neoplasm.